Everolimus (EVE) plus exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study

被引：0

作者：

Jerusalem, Guy Heinrich Maria

Kovalenko, Elena

Yardley, Denise A.

De Boer, Richard H.

Hurvitz, Sara A.

Ejlertsen, Bent

Blau, Sibel

Ozguroglu, Mustafa

Landherr, Laszlo

Ewertz, Marianne

Taran, Tanya

Fan, Jenna

Noel-Baron, Florence

Louveau, Anne-Laure

Burris, Howard A.

机构：

[1] CHU Sart Tilman Liege, Liege, Belgium

[2] Univ Liege, Liege, Belgium

[3] Russian Canc Res Ctr, Moscow, Russia

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Tennessee Oncol PLLC, Nashville, TN USA

[6] Royal Melbourne Hosp, Dept Med Oncol, Melbourne, Vic, Australia

[7] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[8] Copenhagen Univ Hosp, Copenhagen, Denmark

[9] Rainier Hematol Oncol NWMS, Seattle, WA USA

[10] Istanbul Univ, Istanbul, Turkey

[11] Uzsoki Teaching Hosp, Budapest, Hungary

[12] Odense Univ Hosp, Dept Oncol, Odense, Denmark

[13] Novartis Pharmaceut, E Hanover, NJ USA

[14] Novartis Pharmacut Corp, E Hanover, NJ USA

[15] Novartis Pharma SAS, Paris, France

[16] Novartis Pharmaceut, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.1005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1005

引用

页数：2

共 50 条

[1] BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)
Royce, M.
Villanueva, C.
Ozguroglu, M.
Bachelot, T.
Azevedo, S.
Melo Cruz, F.
Hegg, R.
Debled, M.
Gradishar, W. J.
Manlius, C.
Ridolfi, A.
Lin, J.
Ringeisen, F.
Cardoso, F.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[2] Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer The BOLERO-6 Randomized Clinical Trial
Jerusalem, Guy
de Boer, Richard H.
Hurvitz, Sara
Yardley, Denise A.
Kovalenko, Elena
Ejlertsen, Bent
Blau, Sibel
Ozguroglu, Mustafa
Landherr, Laszlo
Ewertz, Marianne
Taran, Tetiana
Fan, Jenna
Noel-Baron, Florence
Louveau, Anne-Laure
Burris, Howard
[J]. JAMA ONCOLOGY, 2018, 4 (10) : 1367 - 1374
[3] Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
Bachelot, T.
Royce, M.
Villanueva, C.
Melo Cruz, F.
Hegg, R.
Falkson, C.
Jeong, J.
Srimuninnimit, V.
Arce, C. H.
Ridolfi, A.
Lin, C.
Gradishar, W.
Ozguroglu, M.
Cardoso, F.
Azevedo, S.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[4] PAM50 intrinsic subtype in hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with exemestane (EXE) in combination with everolimus (EVE) or placebo (PBO): A correlative analysis of the phase III BOLERO-2 trial
Prat, A.
Brase, J. C.
Cheng, Y.
Nuciforo, P.
Pare, L.
Pascual, T.
Martinez, D.
Galvan, P.
Vidal, M.
Adamo, B.
Hortobagyi, G.
Baselga, J.
Ciruelos, E.
[J]. EUROPEAN JOURNAL OF CANCER, 2018, 92 : S117 - S117
[5] Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.
Cardoso, Fatima
Villanueva, Cristian
Royce, Melanie
Cruz, Felipe
Debled, Marc
Hegg, Roberto
Toyama, Tatsuya
Falkson, Carla Isadora
Jeong, Joon
Srimuninnimit, Vichien
Ozguroglu, Mustafa
Gradishar, William John
Azevedo, Sergio J.
Arce, Christina H.
Ridolfi, Antonia
Lin, Chinjune
Bachelot, Thomas Denis
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6] BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR+, HER2- advanced breast cancer
Ejlerteen, Bent
Jerusalem, Guy Heinrich Maria
Hurvits, Sara A.
De Boer, Richard H.
Taran, Tanya
Sahmoud, Tarek
Burris, Howard A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
Piccart, M.
Hortobagyi, G. N.
Campone, M.
Pritchard, K. I.
Noguchi, S.
Rugo, H.
Gnant, M.
Feng, W.
Taran, T.
Baselga, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
[8] Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
Tan, Aihua
Nong, Li
Wang, Hongxue
Jia, Yuxian
Zhong, Wuning
Qin, Fanghui
Wang, Han
Tang, Jing
Liu, Yan
Lu, Yongkui
[J]. CANCER BIOLOGY & THERAPY, 2023, 24 (01)
[9] Alpelisib plus letrozole in estrogen receptor-Positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial
Juric, Dejan
Goncalves, Anthony
Hamilton, Erika
Boni, Valentina
Mayer, Ingrid A.
Turri, Sabine
Wang, Yingbo
Vogl, Florian D.
Sellami, Dalila
Campone, Mario
[J]. CANCER RESEARCH, 2018, 78 (04)
[10] Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.
Constantinidou, Anastasia
Marcou, Yiola
Simmons, Timothy
Bernhisel, Ryan
Hughes, Elisha
Meek, Stephanie
Kakouri, Eleni I.
Georgiou, Georgios
Zouvani, Ioanna
Savvidou, Gabriella
Kuhl, Vanessa
Doedt, Jennifer
Wagner, Susanne
Gutin, Alexander
Lanchbury, Jerry
Kronenwett, Ralf
Rakha, Emad A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →